Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Breast 2Sarcoma 1Plasma cell 1Myeloid 1Gynecologic 1Genitourinary 1

Conditions

Stomach Neoplasms 1Sarcoma 1Lung Neoplasms 1Liposarcoma 1Gastrointestinal Stromal Tumors 1Carcinoma, Transitional Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

Cisplatin 5Carboplatin 5Cyclophosphamide 4Bevacizumab 4130-nm albumin-bound paclitaxel 4pembrolizumab 3Oxaliplatin 3Magnetic Resonance Spectroscopy 3Leucovorin 3Irinotecan 3Gemcitabine 3Fluorouracil 3Docetaxel 3Capecitabine 3tislelizumab 2fludarabine 2Specimen Handling 2Riluzole 2Quality of Life 2Psychiatric Rehabilitation 2Oncolytic Virotherapy 2Observation 2Fluorodeoxyglucose F18 2Fluorescein 2Floxuridine 2Filgrastim 2Drug Therapy 2Cetuximab 2umbralisib 1trifluridine tipiracil drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × pemigatinib × Sarcoma × Clear all
NCT06551896 2024-08-13

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
30 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Lung Neoplasms, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡